At a Glance
- Companies: Remepy, Merck KGaA (Darmstadt)
- Location: US/Israel
- Focus area: Hybrid Drugs (drug + digital therapy)
- Initial target: Rare tumour programmes
- Next steps: Explore broader therapeutic areas
What happened?
Remepy announced a collaboration with Merck KGaA, Darmstadt, Germany on 28 April 2026 to develop Hybrid Drugs — pharmacological treatments combined with personalised digital therapeutic protocols via mobile app. Initial focus on US rare tumour programmes, with potential expansion across Merck’s portfolio.
Why does it matter?
Hybrid Drugs integrate medication with evidence-based AI-driven motor, physical and cognitive interventions, potentially doubling standalone drug effect sizes. Supported by FDA PDURS guidance and SaMD-drug pathways, they enable regulated, reimbursable drug-software combos for superior outcomes in oncology, neurology and beyond.
Who’s behind it?
Remepy pioneers Hybrid Drugs; Merck contributes science/tech expertise. Co-CEO Dr Michal Tsur emphasised regulatory tailwinds differentiating drugs via digital integration.
How was it achieved?
Remepy’s platform pairs pharma with app-delivered adaptive interventions. Early trials show physiological modulation (blood/immune biomarkers); follows Hybridopa Phase 3 Parkinson’s start H2 2026.
What’s next?
Advance rare tumour Hybrid Drugs; expand framework to Merck’s portfolio. Commercialise as single prescription products under evolving regulations.
What are people saying?
Dr Michal Tsur, Remepy Co-CEO: “Excited to collaborate with Merck… new economic model for digital health.” Remepy: “Combines biology, behaviour, technology into single prescription.”